SCHEMBL29614534

SCHEMBL29614534

OCC1[C@H]2CN(c3ncc4c(n3)CNC4)C[C@@H]12

nearest known ligand 0.41

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24421152 1.00 POLB (0.41) POLBSMN1; SMN2
SCHEMBL2810511 0.73 SMN1; SMN2 (0.56) POLBSMN1; SMN2
SCHEMBL2806475 0.71 POLB (0.57) POLBSMN1; SMN2
SCHEMBL2807505 0.70 POLB (0.56) POLBSMN1; SMN2
SCHEMBL904189 0.69 ACACB (0.41) —
SCHEMBL903973 0.68 HDAC3 (0.36) —
SCHEMBL31597922 0.67 POLB (0.49) POLBSMN1; SMN2
SCHEMBL22720338 0.64 SMN1; SMN2 (0.76) POLBSMN1; SMN2
SCHEMBL12769043 0.62 HTR2C (0.34) —
SCHEMBL8203125 0.61 ACACB (0.50) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4240743-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Prelude Therapeutics, Incorporated (US) 2023-09-13 — — EP disclosed
WO-2022099117-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE PRELUDE THERAPEUTICS INCORPORATED (US) 2022-05-12 — — WO disclosed
Send feedback